表紙
市場調査レポート

抗体薬物複合体(ADC)市場における機会の分析

Antibody Drug Conjugate Market Opportunity Analysis

発行 KuicK Research 商品コード 302584
出版日 ページ情報 英文 350 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。

ご注意: DRM (デジタル著作権管理システム) 付PDFになります。制限内容はお問合せください。
Multi-User License: 会社全体での使用権

Back to Top
抗体薬物複合体(ADC)市場における機会の分析 Antibody Drug Conjugate Market Opportunity Analysis
出版日: 2014年05月01日 ページ情報: 英文 350 Pages
概要

抗体薬物複合体(ADC)は、以前では適切な治療法が無かった疾患に苦しむ患者を救う、特別な治療クラスの薬剤へと発展しました。抗体医薬品を使用した治療は、費用が高いということが主要な課題のひとつとして挙げられます。しかし、医療経済の観点からみると、将来においては、その費用対効果は非常に高いものになるはずです。これを実現するためには、薬剤の効果を改善することが重要であり、現在、多くの製薬企業がこの分野に注力しています。brentuximab vedotin(Adcetris)およびado-trastuzumab emtansine(Kadcyla)の承認や、治験パイプライン中に100以上の抗体薬物複合体(ADC)が存在することから、この治療クラスは将来において大きな成長が見込まれています。世界のADC市場は、今後40%を超えるCAGRで拡大し、2020年には68億米ドルに達することが予測されています。

当レポートでは、世界における抗体薬物複合体(ADC)市場の考察、ADCの特許分析、市場発展因子、主要課題、ADCの治験状況などを提供しており、概略以下の構成でお届けします。

第1章 抗体薬物複合体のイントロダクション

第2章 抗体薬物複合体の機序

  • 抗体薬物複合体の成分
  • 抗体薬物複合体の機序

第3章 抗体薬物複合体の必要性

第4章 抗体薬物複合体市場の見通し

  • 市場概要
  • 抗体薬物複合体の臨床パイプライン分析

第5章 抗体薬物複合体市場の力学

  • 市場受容性
  • 取り組むべき課題
  • 将来の成長機会

第6章 抗体薬物複合体の治験状況:段階および標的適応別

  • 研究
  • 前臨床
  • 第1相
  • 第1/2相
  • 第2相
  • 第2/3相
  • 第3相

第7章 上市済みの抗体薬物複合体

第8章 競合情勢

  • ADC Therapeutics
  • Agensys
  • Ambrx
  • Amgen
  • AREVA Med
  • Bayer HealthCare
  • Genentech
  • Immunomedics
  • ImmunoGen
  • Seattle Genetics
目次

Ever since the first attempt in the 1980s to use antibody based drugs as therapeutic agents, the application and use of monoclonal antibody-drug conjugates has evolved in several ways. The major advantage of using Antibody Drug Conjugates (ADC) is that it brings together the best characteristics of both antibodies and the cytotoxic potential of chemotherapy. This offers significant opportunity for the future in terms of targeted accumulation of drug in the tumor cell or tissue.

The Antibody Drug Conjugates has evolved into a special therapeutic class of drugs which can now save patients who suffer from those diseases for which there was no adequate treatment previously. However, one of the major challenges is that the treatment with antibody drugs is highly expensive. From a medical economic perspective, it is most likely that the cost versus value ratio would weigh very high in the future. In order to improve this, it is important that the reliable efficiency of the drugs be proved. Hence, the current market is witnessing an increasing number of pharma companies increasingly focusing their efforts into this field.

With the approvals of brentuximab vedotin(Adcetris) and ado-trastuzumab emtansine (Kadcyla), and more than 100 ADCs in the clinical trial pipeline, the market for this therapeutic class is expected to grow significantly in the future years. It is most likely that the global ADC market would grow at a CAGR of more than 40% to reach USD 6.8 billion by 2020. The other major drivers of the ADC market include the technological advances made in the linker technology and patent fencing. Also, with the entry of large number of companies into this segment, it is likely that competition levels would increase significantly, which would in turn lead to high demand and market value in the years to come.

The Antibody Drug Conjugates market will definitely witness an increase in the partnership and collaborative agreements to develop these drugs. It has been observed that the process of drug development is highly correlated to basic research in Biology and Medicine. Specifically, the details about target molecules and their functions along with their involvement in pathology generally stem from basic research which is conducted in universities and public research institutes. The recent years have thus witnessed a growing relationship between the pharma companies and the academic institutions. Majority of the pharmaceutical companies across the globe have been reducing the size of their departments for basic research. Instead they have started to depend heavily on venture companies and universities, which act as the major source of knowledge.

"Antibody Drug Conjugate Market Opportunity Analysis" Report Highlights:

  • Global ADC Market Insight
  • ADC Patent Analysis
  • Orphan Status & ADC
  • Favorable Market Drivers & Key Issues to be Discussed
  • ADC Clinical Trial Insight by Phase & Target Indications
  • ADC Profiles in Report: 201
  • Majority of ADC in Preclinical Phase: 83
  • Marketed ADC Clinical Profiles

Table of Contents

1. Introduction to Antibody Drug Conjugate

2. Antibody Drug Conjugate Mechanism

  • 2.1. Components of Antibody Drug Conjugate
  • 2.2. Mechanism of Antibody Drug Conjugate

3. Why Need for Antibody Drug Conjugate?

4. Antibody Drug Conjugate Market Outlook

  • 4.1. Market Overview
  • 4.2. Anti Drug Conjugate Clinical Pipeline Analysis

5. Antibody Drug Conjugate Market Dynamics

  • 5.1. Market Acceptability Drivers
  • 5.2. Issues to be Addressed
  • 5.3. Future Growth Opportunities

6. Antibody Drug Conjugate Clinical Trial Insight by Phase & Target Indications

  • 6.1. Research
  • 6.2. Preclinical
  • 6.3. Phase I
  • 6.4. Phase I/II
  • 6.5. Phase II
  • 6.6. Phase II/III
  • 6.7. Phase III

7. Marketed Antibody Drug Conjugate

8. Competitive Landscape

  • 8.1. ADC Therapeutics
  • 8.2. Agensys
  • 8.3. Ambrx
  • 8.4. Amgen
  • 8.5. AREVA Med
  • 8.6. Bayer HealthCare
  • 8.7. Genentech
  • 8.8. Immunomedics
  • 8.9. ImmunoGen
  • 8.10. Seattle Genetics

List of Figures

  • Figure 2-1: Components of Antibody Drug Conjugate
  • Figure 2-2: Mechanism of Antibody Drug Conjugate
  • Figure 4-1: Global Antibody Drug Conjugate Market (US$ Billion), 2013-2020
  • Figure 4-2: Global Adcetris Sales (Million US$), 2013 & 2020
  • Figure 4-3: Adcetris Sales in US & Europe (Million US$), 2013
  • Figure 4-4: Global Kadcyla Sales (Million US$), 2013 & 2020
  • Figure 4-5: Kadcyla Market in US & Ex US (Million US$), 2013
  • Figure 4-6: Antibody Drug Conjugate Clinical Pipeline by Phase (%)
  • Figure 4-7: Antibody Drug Conjugate Clinical Pipeline by Phase (%)

List of Tables

  • Table 8-1: ADC Therapeutics Clinical Pipeline
  • Table 8-2: Agensys Clinical Pipeline
  • Table 8-3: Ambrx Clinical Pipeline
  • Table 8-4: Amgen Clinical Pipeline
  • Table 8-5: AREVA Med Clincal Pipeline
  • Table 8-6: Genentech Clinical Pipeline
  • Table 8-7: Immunomedics Clinical Pipeline
  • Table 8-8: ImmunoGen Clinical Pipeline
  • Table 8-9: Seattle Genetics Clinical Pipeline
Back to Top